Difference between revisions of "International Federation of Pharmaceutical Manufacturers and Associations"

From Powerbase
Jump to: navigation, search
(→‎History and mission)
Line 30: Line 30:
 
== Why are 'public-private partnerships' problematic? ==
 
== Why are 'public-private partnerships' problematic? ==
  
 +
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to:
 +
* The scope and pace of goods moving across borders
 +
* The lack of geographical boundaries for infectious diseases
 +
* The increased possibility for rapid communication (Internet)
 +
* The spread of ideas
 +
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]
  
  

Revision as of 14:50, 24 April 2006

The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [1] It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [2]

History and mission

The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines. The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [3]

The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are:

[4]

Objectives

From the IFPMA website:

"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:

  • to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;
  • to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;
  • to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;
  • to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;
  • to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [5]

Why are 'public-private partnerships' problematic?

For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to:

  • The scope and pace of goods moving across borders
  • The lack of geographical boundaries for infectious diseases
  • The increased possibility for rapid communication (Internet)
  • The spread of ideas
  • World-wide products and marketing" [6]


Individuals

IFPMA President

IFPMA Vice Presidents

[7]

Directors

[8]

Members

Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:

[9]

External links

Retrieved from "https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&oldid=7945"